SFCC Sfbc (MM)

SFBC International, Inc. (NASDAQ:SFCC), a provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, confirmed today that it received a letter from Senator Charles E. Grassley (R-Iowa) requesting additional information from SFBC. SFBC will fully comply with these requests for information. "I first received Senator Grassley's letter, which was dated February 8, 2006, this afternoon," said Jeffrey P. McMullen, chief executive officer of SFBC International. "We have fully cooperated with the Senate committee, and we will continue to do so. Our Company is deeply committed to ensuring the safety and welfare of study participants and the reliability of our studies." The letter stated that its purpose was to follow up on last month's meeting with the Senate Finance Committee staff and former SFBC employees. As a follow-up to the meeting on January 11, 2006, the Committee has requested the company to provide information related to its standard operating procedures at its Miami facility, institutional review boards (IRBs) used by SFBC, human resources, and SFBC employees mentioned in the independent counsel's report dated December 12, 2005, which can be found at SFBC's website, http://www.sfbci.com. In addition, staff members of the United States Senate Committee on Finance requested to interview Arnold Hantman, the company's former chief executive officer, at a mutually agreed upon time at the Committee's office. About SFBC International, Inc. SFBC International, Inc. provides early through late stage clinical drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies around the world. SFBC has more than 30 offices located in North America, Europe (including Central and Eastern Europe), South America, Asia, and Australia. In early clinical development services, SFBC specializes primarily in the areas of Phase I and early Phase II clinical trials and bioanalytical laboratory services, including early clinical pharmacology. SFBC also provides late stage clinical development services globally that focus on Phase II through IV clinical trials. SFBC also offers a range of complementary services, including data management and biostatistics, central laboratory services, medical and scientific affairs, regulatory affairs and submissions, and clinical IT solutions. Additional information is available on SFBC's website at http://www.sfbci.com.